Udenyca
About Udenyca
Biosimilar pegfilgrastim products are developed by Udenyca in the biotechnology sector. These medicines are designed to mitigate neutropenia-related infections in patients undergoing chemotherapy for cancer. Administration options include prefilled syringes and on-body injectors for ease of use. Support services are offered to patients, encompassing educational resources and treatment guidance. Safety data and prescribing details are provided through official channels, with operations centered in the United States pharmaceutical market.
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Coherus Biosciences, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Udenyca
Detailed funding history for Udenyca
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Udenyca
Udenyca has secured backing from 1 investor. Prominent investors backing the company include Intas.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Formulation development, drug manufacturing, and marketing services are provided.
|
Locked | Locked | Locked |
Investor details for Udenyca
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Udenyca
Investment portfolio details for Udenyca
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Udenyca
Detailed financials for Udenyca
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Udenyca Comparisons
Peer comparison for Udenyca
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Udenyca
Detailed competitors of Udenyca
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Udenyca
Complete news archive for Udenyca
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Udenyca
Biosimilar pegfilgrastim products are developed by Udenyca in the biotechnology sector. These medicines are designed to mitigate neutropenia-related infections in patients undergoing chemotherapy for cancer. Administration options include prefilled syringes and on-body injectors for ease of use. Support services are offered to patients, encompassing educational resources and treatment guidance. Safety data and prescribing details are provided through official channels, with operations centered in the United States pharmaceutical market.
Udenyca has 1 investor. Key investors include Intas.